Purple Biotech Ltd. (NASDAQ: PPBT ) stock is surging on Wednesday following a favorable U.S. patent update .
The U.S. Patent and Trademark Office granted the biotechnology company a Notice of Allowance regarding a crucial patent application that covers its tri-specific antibody constructs and their specific methods of application.
Expanding Intellectual Property Defenses
The newly authorized patent substantially broadens the intellectual property portfolio safeguarding Purple Biotech’s proprietary CAPTN-3 platform.
The advanced technology focuses on creating conditionally activated multispecific antibodies for therapeutic applications .
Specifically, the regulatory allowance fortifies the legal protection surrounding the modular architecture that serves as the foundation for the CAPTN-3 platform.
The underlying framework enables scientists to efficiently generate versatile tri-specific antibodies .
It achieves this by allowing the exchange of tumor-associated antigen (TAA) binding domains and various other functional extensions while maintaining a consistent structural backbone.
Read Next Trading IdeasMerck and Moderna Release Landmark Personalized Cancer Therapy Trial Success, Stocks Soar
Merck and Moderna report positive Phase 3 results for their mRNA cancer therapy combined with Keytruda in melanoma patients.
2 min read Read this articleAccelerating Cancer Treatment Development
By leveraging this inherent structural flexibility, the company intends to rapidly accelerate the development timeline for new therapeutic candidates targeting a wide array of cancer indications.
TrendingThe specific claims allowed by the patent office encompass tri-specific antibody constructs that incorporate dual TAA binders alongside other distinguishing features of the CAPTN-3 system .
In April, the cancer immunotherapy company shared new preclinical data supporting the clinical potential of IM1240, the company’s lead CAPTN-3 tri-specific antibody.
The data demonstrated potent anti-tumor activity for IM1240 across multiple treatment-resistant patient-derived tumor samples.
The company aims to start human trials for IM1240 in 2027 .
PPBT Stock Price Activity: Purple Biotech shares were up 22.89% at $2.03 during premarket trading on Wednesday, according to Benzinga Pro data .
Photo via Shutterstock
Read Next MarketsJim Cramer Warns Google’s New AI Tool: ‘Could Be Tough for Adobe’
Jim Cramer warns Google Pics could pressure Adobe as Google launches its AI-powered image creation and editing tool.
2 min read Read this article Market News and Data brought to you by Benzinga APIs© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here .
Posted In: Movers News General Biotech Top Stories Health Care Why It's Moving Retail Investor Stocks